Biogen Inc.

NASDAQ Global Select
Back to all articles
Very Bullish +80

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen

🏢 Biogen Inc. (BIIB) has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (APLS) for approximately $5.6 billion in cash plus potential contingent value rights.

💰 The acquisition price is set at $41.00 per share, representing an 86% premium to the 90-day volume-weighted average stock price and a 35% premium to the 52-week high.

🤝 Apellis shareholders will receive a nontransferable CVR entitling them to two potential payments of $2 per share contingent on global net sales thresholds for SYFOVRE®.

📅 The expected closing of the transaction is scheduled for the second quarter of 2026, following which Biogen plans to update full year 2026 guidance in Q1 earnings.

💼 Apellis brings two commercialized differentiated immunology and rare disease medicines, EMPAVELI® and SYFOVRE®, adding $689 million in combined net sales in 2025.

📈 The combined medicines are expected to grow at a mid-to-high teens rate through 2028, enhancing Biogen's short- and long-term revenue growth profile.

🩺 EMPAVELI® is FDA-approved for rare immune-mediated kidney diseases (C3G and primary IC-MPGN) as well as paroxysmal nocturnal hemoglobinuria (PNH).

👁️ SYFOVRE® is FDA-approved for geographic atrophy secondary to age-related macular degeneration, targeting the complement cascade in retinal disease.

🦠 Both drugs are targeted complement component 3 (C3) therapies designed to regulate excessive activation of the body's immune system complement cascade.

⚕️ The acquisition adds an established U.S. sales infrastructure and nephrology capabilities to accelerate Biogen's commercial readiness for felzartamab in Phase 3 kidney disease trials.

📢 CEO Christopher A. Viehbacher stated the deal immediately advances Biogen's transformation by expanding its growth portfolio in immunology and rare disease.

🏥 Apellis CEO Cedric Francois expressed pride in the team's achievements and noted that Biogen's experience will accelerate impact for SYFOVRE® and EMPAVELI® patients.

📊 The transaction is expected to be increasingly accretive to Non-GAAP diluted EPS starting in 2027 and increase EPS CAGR through the end of the decade.

💸 Biogen plans to finance the acquisition with a combination of cash and borrowings, expecting to de-lever by the end of 2027.

🧬 EMPAVELI® demonstrated a 68% reduction in proteinuria and substantial clearance of C3 deposits in the Phase 3 VALIANT study compared to placebo.

🚀 Upon closing, a significant proportion of Apellis employees are expected to join Biogen, while Sobi retains commercial rights to EMPAVELI® outside the U.S.

Bullish Signals
  • Biogen announced an acquisition of Apellis for approximately $5.6 billion in cash, plus potential earn-outs, significantly enhancing its growth portfolio in immunology and rare disease.
  • The deal adds two commercialized medicines, EMPAVELI® and SYFOVRE®, which generated combined net sales of $689 million in 2025 and are expected to grow at a mid-to-high teens rate through 2028.
  • Apellis brings an established U.S. sales infrastructure that will accelerate Biogen's commercial readiness for felzartamab, currently in Phase 3 studies with the first trial readout expected in the first half of 2027.
  • The transaction is projected to be increasingly accretive to Biogen's Non-GAAP diluted EPS starting in 2027, meaningfully increasing the non-GAAP EPS compounded annual growth rate through the end of the decade.
  • Biogen expects to finance the acquisition with cash and borrowings while maintaining a path to fully de-lever by the end of 2027, preserving financial flexibility for future investments.
  • The combination of Biogen's extensive experience and Apellis' deep expertise in complement science is expected to maximize the potential of their respective medicines and reach more patients.
Risk Factors
  • Biogen plans to finance the acquisition with a combination of cash and borrowings, which will increase leverage before they aim to delever by 2027.
  • A significant proportion of Apellis employees are expected to join Biogen, implying substantial integration risks and potential disruption to operations during the transition.
  • The acquisition price represents an 86% premium to the 90-day volume-weighted average stock price and a 35% premium to the 52-week high, increasing immediate financial pressure on Biogen's balance sheet.
  • The deal relies on Apellis achieving specific annual global net sales thresholds of $5.6 billion to unlock payments related to CVRs for SYFOVRE®.
  • Biogen plans to update full year 2026 guidance only when it reports earnings in the first quarter of 2026, which adds near-term revenue uncertainty before the deal closes later in 2026.
  • The combined entity has recorded $689 million in revenue for EMPAVELI® and SYFOVRE® in 2025, meaning growth projections of mid-to-high teens through 2028 are highly dependent on continued expansion without plateauing.
  • Biogen must integrate Apellis' commercial capabilities to accelerate felzartamab's Phase 3 studies for kidney diseases by the first half of 2027, creating significant time pressure if integration fails.
Full Analysis
Biogen Inc. (NASDAQ: BIIB) has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) for approximately $5.6 billion, consisting of an upfront payment of $41.00 per share in cash and additional contingent value rights (CVRs) tied to sales thresholds for Syfovre. The transaction is expected to close in the second quarter of 2026 following a tender offer by Biogen. This acquisition significantly expands Biogen's portfolio in immunology and rare diseases by adding two FDA-approved complementary cascade therapies: Empaveli and Syfovre, which together generated $689 million in net sales in 2025 and are projected to grow at mid-to-high single-digit or double-digit rates through 2028. Strategically, the deal bolsters Biogen's growth outlook and accelerates its expansion into nephrology by integrating Apellis' established U.S. commercial infrastructure. This integration is specifically intended to strengthen Biogen's commercial readiness for felzartamab, currently in Phase 3 studies for three kidney diseases with an anticipated first trial readout in the first half of 2027. Additionally, a significant proportion of Apellis employees are expected to join Biogen upon closing, while Biogen will continue its working relationship with Sobi, which retains commercial rights to Empaveli outside the U.S. and for certain regions like Europe where it is branded as Aspaveli. Financially, the acquisition is expected to enhance Biogen's short- and long-term revenue growth profile and is projected to be increasingly accretive to Non-GAAP diluted EPS starting in 2027. Management anticipates that the transaction will meaningfully increase Biogen's Non-GAAP EPS compounded annual growth rate (CAGR) through the end of the decade. Biogen plans to finance this acquisition using a combination of cash on hand and borrowings, with a strategy to fully de-leverage by the end of 2027 to maintain financial flexibility for future investments. The company will provide updated full-year 2026 guidance when it reports its Q1 2026 earnings results.